A Clinical Study to Evaluate the Safety and Tolerability of JS012 in Advanced or Metastatic Solid Tumors

Stopped Due to the adjustment and change of the sponsor's R\&D strategy, we now plan to voluntarily terminate this clinical trial.

Conditions

• Advanced or Metastatic Solid Tumors

Interventions

• DRUG: JS012
• COMBINATION_PRODUCT: JS012 combine with chemotherapy

Sponsor

Shanghai Junshi Bioscience Co., Ltd.